“Three Months Ended March 31, (in millions, except per share data) 2026 2025 Operating loss $ (145) $ (131) Interest expense, net (58) (25) Other income, net 14 2 Income tax benefit 29 49 Net loss (160) (105) Less: Net income attributable to noncontrolling interest (32) (18) Net loss attributable to CVR Energy stockholders $ (192) $ (123) Loss per share $ (1.91) $ (1.22) EBITDA (1) $ (52) $ (61) (1) See “Non-GAAP Reconciliations” section below for reconciliations of the non-GAAP measures shown above.”
“The increase in direct external research and development expenses related to zidesamtinib of $6.1 million was primarily due to costs related to the ongoing Phase 2 portion of the ARROS-1 clinical trial and professional services, partially offset by decreased manufacturing costs.”
“If any of the third parties that we rely upon in our recovery/acquisition, distribution or transportation process fail to comply with applicable laws and regulations, fail to meet expected deadlines, or otherwise do not carry out their contractual duties, experience delays due to macroeconomic factors, or encounter physical damage or natural disaster at their facilities, our ability to deliver product to meet commercial demand may be significantly impaired, which could have a material adverse impact on our business, results of operations, financial condition or prospects.”